

Ensayos Clínicos de TIROIDES Abiertos a Reclutamiento en España (Actualizado_Agosto2025)
Información Pública obtenida a partir de: Clinical trials.gov; EU Clinical Trials Register; REEC (AEMPS)

EU-CT Number	NCT	STUDY-Code	TITLE	Phase	INDICACIÓN	STATUS	DRUGS	SITES	SPONSOR
2024-512606-25-00	3093116	TPX-0005-01	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Phase I / II	Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.	RECRUITING	Oral repotrectinib (TPX-0005)	H. Vall d'Hebron (BCN) F. Jimenez Diaz (Madrid) H. 12 de Octubre (Madrid) H.U. Sanchinarro (Madrid) I. Oncologico de Valencia H. Quiron de Xeus (BCN) M.D. Anderson (Madrid) CUN	Turning Point Therapeutics, Inc.
2023-504898-20-00	6235216	SETNE T2318	☑ Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms .	Phase II	SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC) . The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.	RECRUITING	Sacituzumab govitecan	11 Sites	Grupo Espanol de Tumores Neuroendocrinos
2023-507418-28-00	4589845	BO41932	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	Phase II	Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.	RECRUITING	Pralsetinib Entrectinib Belvarafenib	H. Vall d'Hebron (BCN) C.U.N (Navarra) Start-F.J. Diaz (Madrid) Start-Sanchinarro H. 12 de Octubre (Madrid) H.La Paz (Madrid) H. la Fe (Valencia)	Hoffmann-La Roche
2024-514542-37-00	3175224	APL-101-01	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Phase II	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors. Include Thyroid Cancer Cohort .	RECRUITING	APL-101 Oral Capsules	11 Sites	Apollomics Inc.
2022-000627-20	5503797	F8394-201	A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations	Phase II	The objective of this study is to evaluate the efficacy of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare solid tumors, melanoma, thyroid , or recurrent primary CNS tumors harboring BRAF V600E mutation. This will be conducted as four open-label subprotocols (F8394-201A; F8394-201B; F8394-201C; F8394-201D) under one master protocol.	RECRUITING	Plixorafenib Cobicistat	H.U. Vall'Hebron H.U.12 Octubre H.U. Santiago Compostela H.U.Virgen Rocio H.Clinico de Valencia	Fore Biotherapeutics
UNK	6837090	SPAINTRK	Retrospective Analysis of the Experience with Larotrectinib in Patients with Solid Neoplasms with NTRK Fusion in Spain (SPAINTRK)	Restrospective	This is an observational retrospective study including thyroid cancer patients with solid neoplasms with NTRK fusions.	RECRUITING	NA	14 Sites	Grupo Espanol de Tumores Neuroendocrinos